Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 79
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
18 and over
Pharmaceutical / Industry
EGF103659
NCT00338247
Last Modified:
6/12/2008
 
First Published:
5/28/2004
2.
Phase III Randomized Study of Letrozole With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage IV Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
GSK-EGF30008
UCLA-0311034-01, NCT00073528
3.
ErbB2 Over-Expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
EGF104383
NCT00272987
4.
Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
EGF104535
NCT00281658
Last Modified:
1/14/2009
 
First Published:
10/14/2006
5.
Phase III Randomized Study of Fulvestrant With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage III or IV Hormone Receptor-Positive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI
CALGB-40302
NCT00390455
6.
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 70
Pharmaceutical / Industry
EGF102988
NCT00424255
7.
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Treatment
Active
18 and over
Other
NSABP B-41
NCT00486668
8.
Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
20 and over
Pharmaceutical / Industry
104578
NCT00486954
9.
ALTTO(Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation)Study; BIG 2-06/N063D
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI, Pharmaceutical / Industry
EGF106708
BIG 2-06/N063D/MAC13, NCT00490139
10.
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
EGF106903
BIG 1-06, NCT00553358
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute